Effects on thrombin generation of the platelet glycoprotein IIb/IIIa inhibitors abciximab versus tirofiban during coronary intervention

American Journal of Cardiology

Volumn 87, Issue 10, 2001, Pages 1231-1233

  Ambrose, John A ^a   Doss, Ramy ^a   Geagea, Jean Pierre M ^a   Hawkey, Marian C ^a   Duvuri, Srinivas ^a   Giedd, Kenneth ^a   Dominguez, Alvaro ^a   Coppola, John ^a   Nguyen, Tien H ^a   Palla, Venugopal ^a   Barua, Rajat S ^a   Saha, Dhanonjoy C ^a  

^a ST VINCENT S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; INDOMETACIN; PROTHROMBIN; THROMBIN; THROMBOCYTE RECEPTOR; TIROFIBAN;

ACUTE HEART INFARCTION; ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLOOD CLOTTING TIME; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RECEPTOR OCCUPANCY; UNSTABLE ANGINA PECTORIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; ATHERECTOMY, CORONARY; CORONARY DISEASE; FEMALE; HEPARIN; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTHROMBIN; STENTS; THROMBIN; TYROSINE; WHOLE BLOOD COAGULATION TIME;

EID: 0035872892     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(01)01506-5     Document Type: Article

References (14)

1. Use of a monoclonal antibody directed against the platelet GP IIb/IIIa receptor in a high-risk coronary angioplasty. N Engl J Med. 1994;184-199.
2. Platelet GP IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Eng J Med. 336:1997;1689-1696.
3. Effects of platelet GP IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing myocardial infarction undergoing coronary angioplasty. Circulation. 96:1997;1445-1453.
4. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina the CAPTURE study. Lancet. 349:1997;1429-1435.
5. Walsh P.N. Platelet-coagulant protein interactions. Coleman R.W., Hirsh J., Marder V.J., Salzman E.W. Hemostasis & Thrombosis. 1994;629-651 JB Lippincott, Philadelphia, PA.
6. Hayes R., Chesebro J.H., Fuster V., Dangas G., Fallon J.T., Sharma S.K., Coller B.S., Badimon L., Marmur J.D., Badimon J.J. Antithrombotic effects of abciximab. Am J Cardiol. 85:2000;1167-1172.
7. Dangas G., Badimon J.J., Coller B.S., Fallon J.T., Sharma S.K., Hayes R.M., Meraj P., Ambrose J.A., Marmur J.D. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombosis formation and fibrin deposition implications for a potential anticoagulant effect of abciximab. Arterioscler Thromb Vasc Biol. 8:1998;1342-1349.
8. Ambrose J.A., Hawkey M., Badimon J.J., Coppola J., Geagea J.-P., Rentrop K.P., Domiguez A., Duvvuri S., Elmquist T., Arias J., et al. In-vivo demonstration of an antithrombin effect of abciximab. Am J Cardiol. 86:2000;150-152.
9. 3Fab on acute thrombosis and "clinical restenosis." J Clin Invest. 98:1996;863-874.
10. Smith J.W., Steinberg S.R., Lincoff A.M., Coleman J.C., Lee T.T., Hillman R.S., Coller B.S. Rapid platelet-function assay. An automated and quantitative cartridge-based method. Circulation. 99:1999;620-625.
11. Byzova T.V., Plow E.F. Networking in the hemostatic system. Integrin alpha/beta binds prothrombin and influences its activation. J Biol Chem. 272:1997;183-188.
12. Musial J., Radwan J., Szczekhl A. Aspirin delays thrombin generation in vitro through interaction with platelet phospho lipids. Throm Res. 85:1997;367-368.
13. Rao A.K., Sun L., Hiramatsu Y., Gorman J.H. III, Edmunds L.H. Jr. Glycoprotein IIb/IIIa receptor antagonist tirofiban inhibits thrombin generation during cardiopulmonary bypass in baboons. Thromb Haemost. 82:1999;140-144.
14. Kereiakes D.J., Broderick T.M., Roth E.M., Whang D., Shimshak T., Runyon J.P., Hattemer C., Schneider J., Lacock P., Mueller M., Abbottsmith C.W. Time course, magnitude and consistency of platelet inhibition by abciximab, tirofiban or eptifibatide in patients with unstable angina undergoing percutaneous coronary intervention. Am J Cardiol. 84:1999;391-395.